Increlex prescribing information describes a medicine that replaces IGF-1, a signal involved in growth, in children with specific growth disorders. A low IGF-1 result alone isn't its indication, meaning its labeled use. The label also explains serious blood sugar and cancer risks.

Increlex contains mecasermin, a manufactured copy of insulin-like growth factor 1, or IGF-1. That's a signal involved in growth. IGF-1 LR3 is different from FDA-approved Increlex, which isn't a Promise product.

Which Increlex prescribing information is current?

As of November 12, 2026, the day this article was written, the DailyMed record says Updated May 18, 2026, with prescribing information marked “Revised: 10/2025.” The earlier FDA PDF says “Revised: 07/2025.”

These are different versions. DailyMed's listing-update date is separate from the prescribing information's revision date. A 2026 listing update doesn't make this a 2026 clinical revision.

Section 1: who the label covers

The indication is growth failure in children aged 2 or older with either:

  • Severe primary IGF-1 deficiency: very low IGF-1 despite normal or elevated growth hormone, or GH.
  • A missing GH gene and neutralizing antibodies, immune proteins that block GH's action.

The first diagnosis requires height and IGF-1 scores of −3 or lower. These scores describe distance below an age-matched reference average. IGF-1 levels by age explains why a lab result needs context.

Low IGF-1 caused by GH deficiency, poor nutrition, low thyroid function, or certain steroid treatments is outside this indication.

Sermorelin works earlier in the pathway: it signals the pituitary, a small gland beneath the brain, to release GH. Mecasermin supplies IGF-1 directly. The sermorelin versus HGH comparison explains stimulation versus hormone replacement; these medicines aren't interchangeable.

Section 2: dose as a label fact

The label lists a starting dose of 0.04–0.08 mg/kg twice daily by injection under the skin. Mg/kg means milligrams per kilogram of body weight. If tolerated for at least a week, it allows increases up to 0.12 mg/kg twice daily. A doctor experienced in childhood growth disorders sets the actual dose.

The label places injections within 20 minutes before or after food. It requires withholding a dose when the child cannot eat, without larger catch-up doses. Blood sugar checks before meals are recommended when treatment starts and until a tolerated dose is established.

Section 4: contraindications

A contraindication is a reason a medicine must not be used. Increlex's list covers:

  • Allergy to mecasermin or its ingredients, including a previous severe reaction.
  • Growth promotion after the growth plates, the areas where bones lengthen, have closed.
  • Cancer or a history of cancer in children.

The cancer restriction is a contraindication, rather than a suggestion for extra monitoring.

Section 5: warnings that need action

Hypoglycemia means low blood sugar. Severe episodes can cause seizures, unconsciousness, or death. The label says to avoid high-risk activities, such as driving or exercise, within 2 to 3 hours after a dose, particularly while treatment is starting. The patient information calls for emergency medical help right away if a child is unresponsive and cannot drink sugar-containing fluids.

Serious allergy can affect breathing or cause shock. The patient information says to stop Increlex and get medical help right away for those symptoms. Rash or hives calls for contacting the child's doctor right away.

Cancer has been reported after treatment. Whether Increlex causes new cancers is unknown. The warning says “Therapy should be discontinued” if evidence of cancer develops, with expert medical care sought. New growths or cancer symptoms require reporting to the doctor immediately.

Other warnings cover raised pressure inside the skull, enlarged tissue in the nose and throat that can interrupt breathing during sleep, and worsening spinal curvature. Eye examinations and checks for these complications are part of monitoring. A new limp or hip or knee pain requires medical help right away: a hip growth plate can slip and bone tissue can die.

Tesamorelin also signals GH release rather than supplying IGF-1. Its Egrifta label concerns excess abdominal fat in adults with HIV, a virus that weakens immune defenses. That use covers HIV-related fat redistribution, rather than Increlex's childhood growth disorders.

Section 6: adverse reactions in the studies

The label's safety group included 71 children treated for an average of 3.9 years. Selected counts were:

Event during treatment Children affected
Low blood sugar 30 of 71, or 42%
Severe low blood sugar requiring assistance 5
Low-blood-sugar seizures or loss of consciousness 4
Enlarged tonsils 11, or 15%
Raised pressure inside the skull 3

These categories overlap. Fourteen of the 30 children with low blood sugar had experienced it before treatment. The counts don't establish that every event was caused by Increlex.

Section 8: specific populations

Safety and effectiveness are not established below age 2 or at age 65 and older. The benzyl alcohol preservative can cause serious, even fatal, reactions in infants; infant use is not recommended.

There are no human data on pregnancy or whether mecasermin enters breast milk. How kidney or liver disease changes the drug's movement through the body hasn't been studied in these children.

Section 14: what the clinical studies measured

The label combines five studies in 71 children; four were open-label, meaning treatment wasn't hidden from families and researchers. They measured height growth, rather than adult muscle gain or longevity.

A related Chernausek study in the Journal of Clinical Endocrinology & Metabolism, 2007 followed 76 children with GH insensitivity, meaning their bodies didn’t respond normally to GH. Average growth increased from 2.8 centimeters yearly before treatment to 8.0 in the first year. That predominantly open-label study concerns a specific childhood disorder, not healthy adults.

As of November 12, 2026, the day this article was written, a November 2 company release filed with the SEC describes ET-900, a mecasermin program for epileptic spasms, a type of seizure. It reports a submitted application for a clinical study, with first dosing targeted for early 2027. This planned research does not add a labeled use.

Sections 3 and 16: supply and storage

Branded Increlex comes as 40 mg in 4 mL, or 10 mg/mL. Its vial stays refrigerated at 36–46°F (2–8°C), protected from direct light. After first use, the label allows 30 refrigerated days, then requires discarding the remainder. A frozen vial must not be used and must be discarded.

What this label means for compounded medicines

IGF-1 LR3 is a modified molecule, unlike mecasermin's copy of natural human IGF-1. Francis and colleagues' 1992 Journal of Molecular Endocrinology paper studied the modified molecule in cell cultures. Increlex's results cannot establish LR3's human outcomes. IGF-1 LR3 is coming soon to Promise.

Sermorelin and tesamorelin prescribed through Promise are dispensed by a licensed U.S. compounding pharmacy as compounded medications, prepared for an individual prescription. They are different from an FDA-approved product: the formulations offered here are not FDA-approved. Increlex's label does not establish their doses, storage rules, or results.

A licensed provider may still prescribe — that decision is between you and your doctor.

At Promise, a licensed provider reviews every request, and not everyone qualifies. The discussion starts with the person's diagnosis and history, rather than treating a low IGF-1 result as a reason to replace it.